Sulphate-reducing bacteria from ulcerative colitis patients induce apoptosis of gastrointestinal epithelial cells

Microbial Pathogenesis

Volumn 112, Issue , 2017, Pages 126-134

  Coutinho, Cláudia Mara Lara Melo ^a,b,c   Coutinho Silva, Robson ^d   Zinkevich, Vitally ^a   Pearce, Callum B ^e,f   Ojcius, David M ^d,g   Beech, Iwona ^a,h  

^a UNIVERSITY OF PORTSMOUTH   (United Kingdom)

^b FLUMINENSE FEDERAL UNIVERSITY   (Brazil)

^c INSTITUTO OSWALDO CRUZ   (Brazil)

^d FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^e QUEEN ALEXANDRA HOSPITAL   (United Kingdom)

^f MURDOCH UNIVERSITY   (Australia)

^g UNIVERSITY OF THE PACIFIC   (United States)

^h UNIVERSITY OF OKLAHOMA   (United States)

Author keywords

Apoptosis; Human epithelial cells; SRB; Ulcerative colitis

Indexed keywords

EXOPOLYSACCHARIDE; SULFATE;

APOPTOSIS; ARTICLE; CLINICAL ARTICLE; COCULTURE; COLON BIOPSY; COLON EPITHELIUM; CONTROLLED STUDY; DESULFOVIBRIO INDONESIENSIS; ESCHERICHIA COLI; HCT 8 CELL LINE; HUMAN; HUMAN CELL; INTERNALIZATION; INTESTINE EPITHELIUM CELL; NONHUMAN; PRIORITY JOURNAL; SULFATE REDUCING BACTERIUM; ULCERATIVE COLITIS; BACTERIUM; BIOPSY; CELL LINE; COLON; COLONOSCOPY; DESULFOVIBRIO; DRUG EFFECT; EPITHELIUM CELL; FECES; GASTROINTESTINAL TRACT; INFLAMMATORY BOWEL DISEASE; INTESTINE MUCOSA; ISOLATION AND PURIFICATION; METABOLISM; MICROBIOLOGY; PATHOLOGY; UNITED KINGDOM;

APOPTOSIS; BACTERIA; BIOPSY; CELL LINE; COCULTURE TECHNIQUES; COLITIS, ULCERATIVE; COLON; COLONOSCOPY; DESULFOVIBRIO; EPITHELIAL CELLS; ESCHERICHIA COLI; FECES; GASTROINTESTINAL TRACT; HUMANS; INFLAMMATORY BOWEL DISEASES; INTESTINAL MUCOSA; SULFATES; UNITED KINGDOM;

EID: 85030330485     PISSN: 08824010     EISSN: 10961208     Source Type: Journal    
DOI: 10.1016/j.micpath.2017.09.054     Document Type: Article

References (55)

1. Postgate, J.R., The Sulphate-reducing Bacteria. 1984, Cambridge: Cambridge University Press.
2. Coutinho, C.M.L.M., Magalhaes, F.C.M., Araujo-Jorge, T.C., Ultrastructure of sulphidogenic biofilms rich in sulphate-reducing bacteria causing corrosion in the offshore oil extraction platforms off Brazil's atlantic coast. J. Gen. App. Microbiol. 40 (1994), 227–241.
3. Willis, C.L., Gibson, G.R., Allison, C., Macfarlane, S., olt, J.S., Growth, incidence and activities of dissimilatory sulfate-reducing bacteria in the human oral cavity. FEMS Microbiol. Lett. 15 (1995), 267–271.
4. Singh, S.B., Lin, H.C., Hydrogen sulfide in physiology and diseases of the digestive tract. Microorganisms 3 (2015), 866–889.
5. Loubinoux, J., Mory, F., Pereira, I.A., Le Faou, A.E., Bacteremia caused by a strain of Desulfovibrio related to the provisionally named Desulfovibrio fairfieldensis. J. Clin. Microbiol. 38 (2000), 931–934.
6. Shukla, S.K., Reed, K.D., Desulfovibrio desulfuricans bacteremia in a dog. J. Clin. Microbiol. 38 (2000), 1701–1702.
7. Khalil, N.A., Walton, G.E., Gibson, G.R., Tuohy, K.M., Andrews, S.C., In vitro batch cultures of gut microbiota from healthy and ulcerative colitis (UC) subjects suggest that sulphate-reducing bacteria levels are raised in UC and by a protein-rich diet. Int. J. Food Sci. Nutr. 65 (2014), 79–88.
8. Carbonero, F., Benefiel, A.C., Alizadeh-Ghamsari, A.H., Gaskins, H.R., Microbial pathways in colonic sulfur metabolism and links with health and disease. Front. Physiol., 3, 2012, 448, 10.3389/fphys.2012.00448 eCollection;%2012.:448.
9. Macpherson, A.J., Geuking, M.B., McCoy, K.D., Immune responses that adapt the intestinal mucosa to commensal intestinal bacteria. Immunology 115 (2005), 153–162.
10. Macpherson, A.J., Uhr, T., Compartmentalization of the mucosal immune responses to commensal intestinal bacteria. Ann. N. Y. Acad. Sci. 1029 (2004), 36–43.
11. Macpherson, A.J., Uhr, T., Induction of protective IgA by intestinal dendritic cells carrying commensal bacteria. Science 303 (2004), 1662–1665.
12. Kamdar, K., Khakpour, S., Chen, J., Leone, V., Brulc, J., Mangatu, T., Antonopoulos, D.A., Chang, E.B., Kahn, S.A., Kirschner, B.S., Young, G., DePaolo, R.W., Genetic and metabolic signals during acute enteric bacterial infection alter the microbiota and drive progression to chronic inflammatory disease. Cell Host. Microbe 19 (2016), 21–31.
13. Lin, C.S., Chang, C.J., Lu, C.C., Martel, J., Ojcius, D.M., Ko, Y.F., Young, J.D., Lai, H.C., Impact of the gut microbiota, prebiotics, and probiotics on human health and disease. Biomed. J. 37 (2014), 259–268.
14. Pena, J.A., Versalovic, J., Lactobacillus rhamnosus GG decreases TNF-alpha production in lipopolysaccharide-activated murine macrophages by a contact-independent mechanism. Cell Microbiol. 5 (2003), 277–285.
15. Macpherson, A.J., Harris, N.L., Interactions between commensal intestinal bacteria and the immune system. Nat. Rev. Immunol. 4 (2004), 478–485.
16. Tran, V.N., Bourdet-Sicard, R., Dumenil, G., Blocker, A., Sansonetti, P.J., Bacterial signals and cell responses during Shigella entry into epithelial cells. Cell Microbiol. 2 (2000), 187–193.
17. Kim, J.M., Eckmann, L., Savidge, T.C., Lowe, D.C., Witthoft, T., Kagnoff, M.F., Apoptosis of human intestinal epithelial cells after bacterial invasion. J. Clin. Invest. 102 (1998), 1815–1823.
18. Deplancke, B., Gaskins, H.R., Hydrogen sulfide induces serum-independent cell cycle entry in nontransformed rat intestinal epithelial cells. FASEB J. 17 (2003), 1310–1312.
19. Jain, S.K., Peppercorn, M.A., Inflammatory bowel disease and colon cancer: a review. Dig. Dis. 15 (1997), 243–252.
20. Read, A.E., Gastroenterology. Read, A.E., (eds.) Modern Medicine, 1986, 54–109.
21. Gibson, G., Cummings, J.H., Macfarlane, G.T., Growth and activities of sulphate-reducing bacteria in gut contents of healthy subjects and patients with ulcerative colitis. FEMS Microbiol. Ecol. 86 (1991), 103–110.
22. Whitehead, R., Ulcerative colitis. Whitehead, R., (eds.) Gastrointestinal and Oesophageal Pathology, 1989, Churchill Livingstone, New York, 522–531.
23. Ohge, H., Furne, J.K., Springfield, J., Sueda, T., Madoff, R.D., Levitt, M.D., The effect of antibiotics and bismuth on fecal hydrogen sulfide and sulfate-reducing bacteria in the rat. FEMS Microbiol. Lett. 228 (2003), 137–142.
24. Richardson, C.J., Magee, E.A., Cummings, J.H., A new method for the determination of sulphide in gastrointestinal contents and whole blood by microdistillation and ion chromatography. Clin. Chim. Acta 293 (2000), 115–125.
25. Gibson, G.R., Macfarlane, G.T., Cummings, J.H., Sulphate reducing bacteria and hydrogen metabolism in the human large intestine. Gut 34 (1993), 437–439.
26. Fox, J.G., Dewhirst, F.E., Fraser, G.J., Paster, B.J., Shames, B., Murphy, J.C., Intracellular Campylobacter-like organism from ferrets and hamsters with proliferative bowel disease is a Desulfovibrio sp. J. Clin. Microbiol. 32 (1994), 1229–1237.
27. Roediger, W.E., Moore, J., abidge, W., Colonic sulfide in pathogenesis and treatment of ulcerative colitis. Dig. Dis. Sci. 1997:42 (1997), 1571–1579.
28. Levine, J., Furne, J.K.F.A.U., Levitt, M.D., Ashkenazi Jews, sulfur gases, and ulcerative colitis. J. Clin. Gastroenterol. 22 (1996), 288–291.
29. Christl, S.U., Eisner, H.D., Dusel, G., Kasper, H., Scheppach, W., Antagonistic effects of sulfide and butyrate on proliferation of colonic mucosa: a potential role for these agents in the pathogenesis of ulcerative colitis. Dig. Dis. Sci. 41 (1996), 2477–2481.
30. Devkota, S., Wang, Y., Musch, M.W., Leone, V., Fehlner-Peach, H., Nadimpalli, A., Antonopoulos, D.A., Jabri, B., Chang, E.B., Dietary-fat-induced taurocholic acid promotes pathobiont expansion and colitis in Il10-/- mice. Nature 487 (2012), 104–108.
31. Teramoto, F., Rokutan, K., Kawakami, Y., Fujimura, Y., Uchida, J., Oku, K., Oka, M., Yoneyama, M., Effect of 4G-beta-D-galactosylsucrose (lactosucrose) on fecal microflora in patients with chronic inflammatory bowel disease. J. Gastroenterol. 31 (1996), 33–39.
32. Gibson, G.R., Roberfroid, M.B., Dietary modulation of the human colonic microbiota: introducing the concept of prebiotics. J. Nutr. 125 (1995), 1401–1412.
33. Burke, A., Lichtenstein, G.R., Rombeau, J.L., Nutrition and ulcerative colitis. Baillieres Clin. Gastroenterol., 1997, 153–174.
34. Pitcher, M.C., Beatty, E.R., Cummings, J.H., The contribution of sulphate reducing bacteria and 5-aminosalicylic acid to faecal sulphide in patients with ulcerative colitis. Gut 46 (2000), 64–72.
35. Zinkevich, V.V., Beech, I.B., Screening of sulfate-reducing bacteria in colonoscopy samples from healthy and colitic human gut mucosa. FEMS Microbiol. Ecol. 34 (2000), 147–155.
36. Poxton, I.R., Brown, R., Sawyerr, A., Ferguson, A., Mucosa-associated bacterial flora of the human colon. J. Med. Microbiol. 46 (1997), 85–91.
37. Feio, M.J., Beech, I.B., Carepo, M., Lopes, J., Cheung, S., Franco, R., Guezennec, J., Smith, J., Mitchell, J., Moura, J.J.G., Lino, A.R., Isolation and characterisation of a novel sulphate-reducing bacterium of the Desulfovibrio genus. Anaerobe 4 (1998), 117–130.
38. Bouma, G., Strober, W., The immunological and genetic basis of inflammatory bowel disease. Nat. Rev. Immunol. 3 (2003), 521–533.
39. Strober, W., Fuss, I.J., lumberg, R.S., The immunology of mucosal models of inflammation. Annu. Rev. Immunol. 20 (2002), 495–549.
40. Hulten, K., Almashhrawi, A., El-Zaatari, F.A., Graham, D.Y., Antibacterial therapy for Crohn's disease: a review emphasizing therapy directed against mycobacteria. Dig. Dis. Sci. 45 (2000), 445–456.
41. Dzierzewicz, Z., Cwalina, B., Weglarz, L., Wisniowska, B., Szczerba, J., Susceptibility of Desulfovibrio desulfuricans intestinal strains to sulfasalazine and its biotransformation products. Med. Sci. Monit. 10 (2004), 185–190.
42. Edmond, L.M., Hopkins, M.J., Magee, E.A., Cummings, J.H., The effect of 5-aminosalicylic acid-containing drugs on sulfide production by sulfate-reducing and amino acid-fermenting bacteria. Inflamm. Bowel. Dis 9 (2003), 10–17.
43. Swidsinski, A., Ladhoff, A., Pernthaler, A., Swidsinski, S., Loening-Baucke, V., Ortner, M., Weber, J., Hoffmann, U., Schreiber, S., Dietel, M., Lochs, H., Mucosal flora in inflammatory bowel disease. Gastroenterology 122 (2002), 44–54.
44. Loubinoux, J., Bronowicki, J.P., Pereira, I.A.C., Mougenel, J.L., Le Faou, A.E., Sulfate-reducing bacteria in human feces and their association with inflammatory bowel diseases. FEMS Microbiol. Ecol. 40 (2002), 107–112.
45. Martin, H.M., Campbell, B.J., Hart, C.A., Mpofu, C., Nayar, M., Singh, R., Englyst, H., Williams, H.F., Rhodes, J.M., Enhanced Escherichia coli adherence and invasion in Crohn's disease and colon cancer. Gastroenterology 127 (2004), 80–93.
46. Szabo, C., Ransy, C., Modis, K., Andriamihaja, M., Murghes, B., Coletta, C., Olah, G., Yanagi, K., Bouillaud, F., Regulation of mitochondrial bioenergetic function by hydrogen sulfide. Part I. Biochemical and physiological mechanisms. Br. J. Pharmacol. 171 (2014), 2099–2122.
47. Baskar, R., Bian, J., Hydrogen sulfide gas has cell growth regulatory role. Eur. J. Pharmacol. 656 (2011), 5–9.
48. Chen, S.W., Zhu, J., Zuo, S., Zhang, J.L., Chen, Z.Y., Chen, G.W., Wang, X., Pan, Y.S., Liu, Y.C., Wang, P.Y., Protective effect of hydrogen sulfide on TNF-alpha and IFN-gamma-induced injury of intestinal epithelial barrier function in Caco-2 monolayers. Inflamm. Res. 64 (2015), 789–797.
49. Ward, J.M., Anver, M.R., Haines, D.C., Melhorn, J.M., Gorelick, P., Yan, L., Fox, J.G., Inflammatory large bowel disease in immunodeficient mice naturally infected with Helicobacter hepaticus. Lab. Anim. Sci. 46 (1996), 15–20.
50. Lodes, M.J., Cong, Y., Elson, C.O., Mohamath, R., Landers, C.J., Targan, S.R., Fort, M., Hershberg, R.M., Bacterial flagellin is a dominant antigen in Crohn disease. J. Clin. Invest. 113 (2004), 1296–1306.
51. Zhang-Sun, W., Augusto, L.A., Zhao, L., Caroff, M., Desulfovibrio desulfuricans isolates from the gut of a single individual: structural and biological lipid A characterization. FEBS Lett. 589 (2015), 165–171.
52. Li, L., Bhatia, M., Zhu, Y.Z., Zhu, Y.C., Ramnath, R.D., Wang, Z.J., Anuar, F.B., Whiteman, M., Salto-Tellez, M., Moore, P.K., Hydrogen sulfide is a novel mediator of lipopolysaccharide-induced inflammation in the mouse. FASEB J. 19 (2005), 1196–1198.
53. Hart, A.L., Stagg, A.J., Kamm, M.A., Use of probiotics in the treatment of inflammatory bowel disease. J. Clin. Gastroenterol. 36 (2003), 111–119.
54. Kruis, W., Fric, P., Pokrotnieks, J., Lukas, M., Fixa, B., Kascak, M., Kamm, M.A., Weismueller, J., Beglinger, C., Stolte, M., Wolff, C., Schulze, J., Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut 53 (2004), 1617–1623.
55. Figliuolo, V.R., Dos Santos, V.L., Abalo, A., Nanini, R., Santos, A., Brittes, N.N., Bernardazzi, C., De Souza, H.S., Vieira, L.Q., Coutinho-Silva, R., Coutinho, C.M.L.M., Sulfate-reducing bacteria stimulate gut immune responses and contribute to inflammation in experimental colitis. Life Sci. 189 (2017), 29–38.